We are pleased to provide you with the May 2014 issue of the HotSheet. You may have noticed that last week we also distributed the latest collection of prostate cancer articles sent to you as News You Can Use. Moving forward we’ll continue sending these prostate cancer news updates to you every month on a regular basis approximately two weeks after distribution of the HotSheet. This reflects the transition of our news provider to a new and improved platform which should help us serve you better.
Thanks again for the outpouring of enthusiasm from volunteers who are helping to respond to calls we receive on the Us TOO Prostate Cancer HelpLine! After the three calls we did a few weeks ago, we’re planning our next conference call to review the guidelines of the program with additional volunteers on April 30th. We are excited that this effort will also help us serve more people in the prostate cancer community.
I was in Washington, DC, on April 9-10 to attend the NCCS (National Coalition for Cancer Survivorship) Industry Policy Roundtable “think tank” meetings with fellow stakeholders in the cancer community to hear the latest updates on Obama Care/ACA (Affordable Care Act) implementation, issues with the FDA and other policy issues. Such meetings offer us the opportunity to keep the prostate cancer community informed on developing policy issues and we appreciate the support from NCCS to make our involvement possible.
We’re making plans to attend the AUA (American Urological Association) annual conference in Orlando May 16 to 21 and the annual ASCO (American Society for Clinical Oncology) conference in Chicago May 30 to June 3 to raise awareness of Us TOO with cancer doctors and researchers. We have recently been collaborating with Jan Manarite from PCRI and representatives from the SNMMI (Society of Nuclear Medicine and Molecular Imaging) to plan a Chicago Nuclear Medicine and Imaging Conference at Northwestern University in July. Stay tuned for more details.
We’re also gearing up for men’s health awareness month in June, which coincides with our semi-annual fundraising campaign to generate money for Us TOO’s work. Continuation of our mission to provide support, education and advocacy to the prostate cancer community at no charge depends in large part on donations from individuals. Thank you for helping us to tackle this ongoing challenge.
We are saddened by the passing of Jennifer Joan Simons, board chairman at The Prostate Net. She passed away on April 18, 2014 in Barcelona, Spain, after a nine-year fight against an atypical benign meningioma tumor of the brain. We extend our condolences to her family, friends and her husband, Virgil, founder and president of The Prostate Net and prostate cancer survivor.
Finally, we wanted to share that Bayer HealthCare Pharmaceuticals Inc. is currently seeking to enroll approximately 800 patients in a clinical trial studying Xofigo® (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC). The randomized, double-blind, placebo-controlled Phase 3 trial is designed to determine the effects of this combination treatment on symptomatic skeletal event-free survival. Further information about the study can be found by searching NCT02043678 at www.clinicaltrials.gov.
My best to you all,
President & CEO
Us TOO International
Downers Grove, IL 60655
Toll Free: 800-808-7866